ChREBP regulates fructose-induced glucose production independently of insulin signaling
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Obese, insulin-resistant states are characterized by a paradoxical pathogenic condition in which the liver appears to be selectively insulin resistant. Specifically, insulin fails to suppress glucose production, yet successfully stimulates de novo lipogenesis. The mechanisms underlying this dysregulation remain controversial. Here, we hypothesized that carbohydrate-responsive element-binding protein (ChREBP), a transcriptional activator of glycolytic and lipogenic genes, plays a central role in this paradox. Administration of fructose increased hepatic hexose-phosphate levels, activated ChREBP, and caused glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis in mice. Activation of ChREBP was required for the increased expression of glycolytic and lipogenic genes as well as glucose-6-phosphatase (G6pc) that was associated with the effects of fructose administration. We found that fructose-induced G6PC activity is a major determinant of hepatic glucose production and reduces hepatic glucose-6-phosphate levels to complete a homeostatic loop. Moreover, fructose activated ChREBP and induced G6pc in the absence of Foxo1a, indicating that carbohydrate-induced activation of ChREBP and G6PC dominates over the suppressive effects of insulin to enhance glucose production. This ChREBP/G6PC signaling axis is conserved in humans. Together, these findings support a carbohydrate-mediated, ChREBP-driven mechanism that contributes to hepatic insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is in line with the results from some studies in that hepatic esterification of FAs into TG, unlike DNL, depends on substrate delivery rather than insulin action [84-86].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [86]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ChREBPβ is transcriptionally induced by ChREBPα and amplifies the glucose response in the liver and adipose tissue [78,86].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this perspective, monosaccharides have been shown to activate ChREBP and other key lipogenic transcription factors—including SREBP1c, LXR, and PPARγ—via insulin-independent mechanisms [34,70,83,86,99].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the Western diet not only contains large amounts of AGEs, due to high levels of food processing, but is also high in fat and sugar, particularly fructose, which increases AGE production in the body, in part, by increasing circulating glucose levels via enhanced hepatic glucose production and insulin resistance.[4]”
From The Role of Dietary Advanced Glycation End Products in Metabolic Dysfunction (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In response to the intake of large carbohydrates, fructose could enhance hepatic lipogenic capacity by inducing hepatic master transcription factors.93 94 95”
From Dietary sugar consumption and health: umbrella review (2023) · cites this paper as [94]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism
Taniguchi, C. M., Ueki, K., & Kahn, C. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23187 · Cited by 272
RetractedA SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“These studies do not address the observation that hyperinsulinemia fails to suppress hepatic glucose-6-phosphatase ( G6PC ) expression in insulin-resistant humans (12), a condition where increased DNL in association with steatosis and hypertriglyceridemia is readily apparent (13, 14).”
BackgroundSugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes
Malik, V. S., Popkin, B. M., Bray, G. A., Després, J.-P., Willett, W. C., & Hu, F. B. (2010) · Diabetes Care · doi:10.2337/dc10-1079 · Cited by 2,116
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322 · cited 1×
“However, others reported that defects in hepatic insulin signaling occur at the level of the insulin receptor, proximal to the proposed branch points in insulin signaling, thereby precluding differential insulin signaling as a mechanism to explain this paradox (7).”
Background
Cited by
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
Jensen, T., Abdelmalek, M. F., Sullivan, S., Nadeau, K. J., Green, M., Roncal, C., Nakagawa, T., Kuwabara, M., Sato, Y., Kang, D.-H., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.019 · Cited by 941
“The stimulation of ChREBP results in the stimulation of glucose-6phosphatase that may mediate some of the gluconeogenic effects of fructose.(112) We also documented that fructose-induced uric acid can impair fatty acid oxidation.”
The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids
Jang, C., Hui, S., Lu, W., Cowan, A. J., Morscher, R. J., Lee, G., Liu, W., Tesz, G. J., Birnbaum, M. J., & Rabinowitz, J. D. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.12.016 · Cited by 639
“Another possible mechanism by which fructose may induce liver toxicity is via itself reaching the liver (Kim et al., 2016; Zhang et al., 2017).”
BackgroundFructose metabolism and metabolic disease
Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96702 · Cited by 561
“We recently demonstrated that ingesting fructose, but not glucose, acutely and robustly induces hepatic expression of the potent ChREBP-β isoform along with its lipogenic, fructolytic, and glycolytic targets (133, 134).”
BackgroundInfluentialSelf-citationInsulin signaling in health and disease
Saltiel, A. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142241 · Cited by 446
Unraveling the Regulation of Hepatic Metabolism by Insulin
Titchenell, P. M., Lazar, M. A., & Birnbaum, M. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.03.003 · Cited by 437
“Dietary fructose administration induces hepatic steatosis, an effect dependent on ChREBP [26].”
BackgroundFructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease
Ter Horst, K., & Serlie, M. (2017) · Nutrients · doi:10.3390/nu9090981 · Cited by 365
“In addition, fructose activates ChREBP and promotes hepatic gluconeogenesis independently of hepatic insulin signaling, which may contribute to hepatic insulin resistance (Figure 3) [58].”
BackgroundInfluentialWhite, P. J., McGarrah, R. W., Grimsrud, P. A., Tso, S.-C., Yang, W.-H., Haldeman, J. M., Grenier-Larouche, T., An, J., Lapworth, A. L., Astapova, I., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.015 · Cited by 365
“(D) Mouse (m) ChREBP-b and rat (r) Bckdk (BDK), and PPM1KmRNA expression means ± SEM, n = 6–8 rats per group.”
InfluentialSelf-citationDivergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling
Softic, S., Gupta, M. K., Wang, G.-X., Fujisaka, S., O’Neill, B. T., Rao, T. N., Willoughby, J., Harbison, C., Fitzgerald, K., Ilkayeva, O., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94585 · Cited by 347
Dietary sugar consumption and health: umbrella review
Huang, Y., Chen, Z., Chen, B., Li, J., Yuan, X., Li, J., Wang, W., Dai, T., Chen, H., Wang, Y., et al. (2023) · BMJ · doi:10.1136/bmj-2022-071609 · Cited by 348
Bu, P., Chen, K.-Y., Xiang, K., Johnson, C., Crown, S. B., Rakhilin, N., Ai, Y., Wang, L., Xi, R., Astapova, I., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.003 · Cited by 324
“ALDOB is in part rate-limiting for fructose metabolism within the liver as shown by large increases in F1P levels in the liver after administration of large fructose loads (Kim et al., 2016; Niewoehner et al., 1984).”
BackgroundSelf-citationDietary Fructose and the Metabolic Syndrome
Taskinen, M.-R., Packard, C. J., & Borén, J. (2019) · Nutrients · doi:10.3390/nu11091987 · Cited by 295
“ChREBP regulates fructose-induced glucose production independently of insulin signaling [22], and the fructose-induced increases in circulating fibroblast growth factor 21 (FGF21) [55].”
BackgroundMolecular aspects of fructose metabolism and metabolic disease
Herman, M. A., & Birnbaum, M. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.010 · Cited by 290
Self-citationGlucose transporters in the small intestine in health and disease
Koepsell, H. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02439-5 · Cited by 290
Schwarz, J.-M., Noworolski, S. M., Erkin-Cakmak, A., Korn, N. J., Wen, M. J., Tai, V. W., Jones, G. M., Palii, S. P., Velasco-Alin, M., Pan, K., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.043 · Cited by 266
Fructose and hepatic insulin resistance
Softic, S., Stanhope, K. L., Boucher, J., Divanovic, S., Lanaspa, M. A., Johnson, R. J., & Kahn, C. R. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1711360 · Cited by 251
“Even though ChREBP transcriptional activity is mediated by glucose, fructose can also activate ChREBP [35] by inducing a second promoter in the ChREBP gene and an alternative splicing event to yield the ChREBP-b isoform [36].”
BackgroundGeidl-Flueck, B., Hochuli, M., Németh, Á., Eberl, A., Derron, N., Köfeler, H. C., Tappy, L., Berneis, K., Spinas, G. A., & Gerber, P. A. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.027 · Cited by 238
Aragno, M., & Mastrocola, R. (2017) · Nutrients · doi:10.3390/nu9040385 · Cited by 239
“S veral studies have dem strated that exc ssive fructose consumption is associ te with increased ectopic lipid deposition in l ver and skeletal muscle b th in experimental models and in humans [48,49,54,55], and that fru tose is able to promote hepatic lipogenesis [56,57] by inducing the expression and activation of t…”
BackgroundLinden, A. G., Li, S., Choi, H. Y., Fang, F., Fukasawa, M., Uyeda, K., Hammer, R. E., Horton, J. D., Engelking, L. J., & Liang, G. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m081836 · Cited by 231
Sweet Sixteenth for ChREBP: Established Roles and Future Goals
Abdul-Wahed, A., Guilmeau, S., & Postic, C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.004 · Cited by 231
“…a recent interesting study from Herman’s laboratory places ChREBP as a key mediator of fructoseinduced dysregulation of hepatic glucose production, through direct upregulation of G6pc gene encoding the catalytic subunit of key gluconeogenic enzyme glucose 6-phosphatase (Kim et al., 2016).”
BackgroundResultInfluentialHigh Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions
Zhang, D.-M., Jiao, R.-Q., & Kong, L.-D. (2017) · Nutrients · doi:10.3390/nu9040335 · Cited by 228
“Liver Steatosis NAFLD Fibrogenesis Endothelial dysfunction Lactate FFA DAG Ceramide UA MG Gluconeogenesis Glucose export ROS production DNL Inflammatory cytokine flux Lipid accumulation Mitochondrial dysfunction VLDL-secretion Insulin sensitivity Glucose consumption Glucose uptake Oxygen availability IRS/PI3K/Akt, ChR…”
BackgroundSoftic, S., Meyer, J. G., Wang, G.-X., Gupta, M. K., Batista, T. M., Lauritzen, H. P. M. M., Fujisaka, S., Serra, D., Herrero, L., Willoughby, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.003 · Cited by 227
“Fructose containing sugars modulate mRNA of lipogenic genes ACC and FAS and protein levels of transcription factors ChREBP and SREBP1c with no effect on body weight or liver fat.”
BackgroundInfluentialMetabolic drivers of non-alcoholic fatty liver disease
Bence, K. K., & Birnbaum, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101143 · Cited by 221
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 213
“ChREBP is also induced in liver by dietary fructose, a major source of calories in “Western” obesogenic diets (54, 55).”
BackgroundThe Role of Dietary Advanced Glycation End Products in Metabolic Dysfunction
Sergi, D., Boulestin, H., Campbell, F. M., & Williams, L. M. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900934 · Cited by 194
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism
Fisher, F. M., Kim, M., Doridot, L., Cunniff, J. C., Parker, T. S., Levine, D. M., Hellerstein, M. K., Hudgins, L. C., Maratos-Flier, E., & Herman, M. A. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.11.008 · Cited by 166
Self-citationThe small intestine shields the liver from fructose-induced steatosis
Jang, C., Wada, S., Yang, S., Gosis, B., Zeng, X., Zhang, Z., Shen, Y., Lee, G., Arany, Z., & Rabinowitz, J. D. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0222-9 · Cited by 160
Carbohydrate Sensing Through the Transcription Factor ChREBP
Ortega-Prieto, P., & Postic, C. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00472 · Cited by 162
“This effect could lead to a vicious cycle in which fructose consumption exacerbates glucose production though ChREBP activity (Kim et al., 2016).”
BackgroundGlucose-6 Phosphate, a Central Hub for Liver Carbohydrate Metabolism
Rajas, F., Gautier‐Stein, A., & Mithieux, G. (2019) · Metabolites · doi:10.3390/metabo9120282 · Cited by 173
“Recent studies have also supported the importance of ChREBP in the regulation of fructose metabolism [48,49].”
BackgroundDietary Fructose and Fructose-Induced Pathologies
Jung, S., Bae, H., Song, W., & Jang, C. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062220-025831 · Cited by 172
Recent advances in fructose intake and risk of hyperuricemia
Zhang, C., Li, L., Zhang, Y., & Zeng, C. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110795 · Cited by 157
Andrés-Hernando, A., Orlicky, D. J., Kuwabara, M., Ishimoto, T., Nakagawa, T., Johnson, R. J., & Lanaspa, M. A. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.05.012 · Cited by 126
“, 2018), which is largely mediated by preventing fructose-induced lipogenesis, mitochondrial dysfunction and adenine nucleotide turnover (Herman and Samuel, 2016; Kim et al., 2016; Lanaspa et al., 2018a; Lanaspa et al., 2012a; Lanaspa et al., 2012b; Lanaspa et al., 2012c; Softic et al., 2019).”
BackgroundThe role of ChREBP in carbohydrate sensing and NAFLD development
Régnier, M., Carbinatti, T., Parlati, L., Benhamed, F., & Postic, C. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00809-4 · Cited by 101
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction
Gutierrez, J. A., Liu, W., Perez, S., Xing, G., Sonnenberg, G., Kou, K., Blatnik, M., Allen, R., Weng, Y., Vera, N. B., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101196 · Cited by 93
Self-citationMedical Nutrition Therapy for Post-Bariatric Hypoglycemia: Practical Insights
Suhl, E., Anderson-Haynes, S.-E., Mulla, C., & Patti, M.-E. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.01.025 · Cited by 96
“Fructose can stimulate both incretin and insulin secretion [19], but differential absorption patterns and hepatic metabolism of fructose versus glucose could contribute to differential prandial glucose patterns [20].”
Intestinal, but not hepatic, ChREBP is required for fructose tolerance
Kim, M., Astapova, I. I., Flier, S. N., Hannou, S. A., Doridot, L., Sargsyan, A., Kou, H. H., Fowler, A. J., Liang, G., & Herman, M. A. (2017) · JCI Insight · doi:10.1172/jci.insight.96703 · Cited by 93
Self-citationCohen, C. C., Li, K. W., Alazraki, A. L., Beysen, C., Carrier, C., Cleeton, R. L., Dandan, M., Figueroa, J., Knight‐Scott, J., Knott, C. J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150996 · Cited by 92
“In particular, while glucose has a more systemic initial metabolic uptake (30, 31), fructose is primarily metabolized in the liver (32), where it contributes carbon substrates to hepatic pyruvate, acetyl-CoA, and DNL, and may indirectly stimulate DNL by transcriptional regulation via carbohydrate response element–bind…”
BackgroundInsights into the Hexose Liver Metabolism—Glucose versus Fructose
Geidl-Flueck, B., & Gerber, P. (2017) · Nutrients · doi:10.3390/nu9091026 · Cited by 85
“Feeding studies comparing the potency of fructose versus glucose to induce ChREBP expression have shown different outcomes: two studies report that fructose more potently induced ChREPB expression [64,65], whereas another study reported no differences [85].”
BackgroundResultInfluentialIizuka, K. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.029 · Cited by 91
“very recently reported that fructose administration increases expression of G6pc mRNA by ChREBP activation, which results in increased hepatic glucose output [66].”
BackgroundInfluentialYang, W., Jiang, W., & Guo, S. (2023) · Nutrients · doi:10.3390/nu15214671 · Cited by 117
“Administration of fructose to mice significantly increases the activity of carbohydrate-responsive element-binding protein (ChREBP) and sterol regulatory element-binding protein 1 (SREBP-1c), two important transcription factors stimulating lipogenesis [89,90].”
BackgroundTruong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“Moreover, fructose—a substrate that enters hepatocytes independently of insulin—ro-bustly induced gene expression of the active ChREBPβ isoform and stimulated hepatic lipogenesis in obese individuals regardless of MASLD status [70,86].”
InfluentialIizuka, K. (2017) · Nutrients · doi:10.3390/nu9020181 · Cited by 85
“G6pc mRNA expression is decreased in Chrebp−/− mice [20,21,64], and some studies have reported that ChREBP directly regulates G6pc gene expression in hepatocytes [72].”
BackgroundThe Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
Federico, A., Rosato, V., Masarone, M., Torre, P., Dallio, M., Romeo, M., & Persico, M. (2021) · Nutrients · doi:10.3390/nu13041314 · Cited by 91
“Furthermore, as evidence of the independence of fructose from suppressive effects of insulin, the ChREBP-mediated induction of G6Pase also occurs in absence of the transcription factor forkhead box O1a (FoxO1), which transactivates gluconeogenic enzymes expression and is inhibited by insulin [54].”
BackgroundBile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 90
Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat, N., & Mani, A. (2023) · Nutrients · doi:10.3390/nu15102323 · Cited by 92
“Increased levels of glycolytic intermediates such as glucose 6-phosphate, fructose, and the pentose phosphate pathway intermediate xylulose-5-phosphate activate the transcription factors carbohydrate response element binding protein 1a (ChRebp1a) and ChRebp1b [85,90,92–94].”
BackgroundFructose drives de novo lipogenesis affecting metabolic health
Geidl, B., & Gerber, P. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0270 · Cited by 103
The Complex Roles of Mechanistic Target of Rapamycin in Adipocytes and Beyond
Lee, P. L., Jung, S. M., & Guertin, D. A. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.01.004 · Cited by 64
Fatty liver and FGF21 physiology
Maratos–Flier, E. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.05.006 · Cited by 74
Buziau, A. M., Schalkwijk, C. G., Stehouwer, C. D. A., Tolan, D. R., & Brouwers, M. C. G. J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03348-2 · Cited by 70
Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets
Katz, L. S., Baumel-Alterzon, S., Scott, D. K., & Herman, M. A. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100623 · Cited by 62
“This includes the terminal step in gluconeogenesis catalyzed by glucose-6-phosphatase (G6PC) (13, 62, 71, 72).”
BackgroundInfluentialSelf-citationRecent insights into the role of ChREBP in intestinal fructose absorption and metabolism
Lee, H.-J., & Cha, J.-Y. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.9.197 · Cited by 64
“increased glycolytic, fructolytic, and lipogenic gene expression (52, 53).”
BackgroundDiscovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK)
Huard, K., Ahn, K., Amor, P. A., Beebe, D. A., Borzilleri, K. A., Chrunyk, B. A., Coffey, S. B., Cong, Y., Conn, E. L., Culp, J. S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00947 · Cited by 55
HCF-1 Regulates De Novo Lipogenesis through a Nutrient-Sensitive Complex with ChREBP
Lane, E. A., Choi, D. W., García-Haro, L., Levine, Z. G., Tedoldi, M., Walker, S., & Danial, N. N. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.019 · Cited by 64
“However, ChREBP phosphomutants remain glucose responsive (Tsatsos and Towle, 2006), and a pool of ChREBP resides in the nucleus even in the absence of glucose stimulation (Kim et al., 2016), indicating the existence of additional glucose-dependent regulatory mechanisms.”
Charidemou, E., Ashmore, T., Li, X., McNally, B. D., West, J. A., Liggi, S., Harvey, M., Orford, E., & Griffin, J. L. (2019) · JCI Insight · doi:10.1172/jci.insight.124819 · Cited by 52
“Glucose also stimulates the expression of anabolic DNL genes, including those encoding ATP-citrate lyase (ACL), ACC, and FAS (ACLY, ACACA, and FASN, respectively) by the action of the transcription factor carbohydrate response element–binding protein (ChREBP) (7).”
BackgroundTranscriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 58
“ChREBPα is directly activated by glucose, independently from insulin signaling [98].”
BackgroundInsulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
Retinol saturase coordinates liver metabolism by regulating ChREBP activity
Heidenreich, S., Witte, N., Weber, P., Göhring, I., Tolkachov, A., von Loeffelholz, C., Döcke, S., Bauer, M. W., Stockmann, M., Pfeiffer, A. F. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00430-w · Cited by 56
ChREBP deficiency leads to diarrhea-predominant irritable bowel syndrome
Oh, A.-R., Sohn, S., Lee, J., Park, J.-M., Nam, K. T., Hahm, K.-B., Kim, Y.-B., Lee, H.-J., & Cha, J.-Y. (2018) · Metabolism · doi:10.1016/j.metabol.2018.04.006 · Cited by 49
“influx of fructose itself into the liver [42, 43].”
BackgroundZhang, S., Guo, F., Yu, M., Yang, X., Yao, Z., Li, Q., Wei, Z., Feng, K., Zeng, P., Zhao, D., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.034 · Cited by 49
ChREBP is activated by reductive stress and mediates GCKR-associated metabolic traits
Singh, C., Jin, B., Shrestha, N., Markhard, A. L., Panda, A., Calvo, S. E., Deik, A., Pan, X., Zuckerman, A. L., Saad, A. B., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.010 · Cited by 52
ChREBP-Knockout Mice Show Sucrose Intolerance and Fructose Malabsorption
Kato, T., Iizuka, K., Takao, K., Horikawa, Y., Kitamura, T., & Takeda, J. (2018) · Nutrients · doi:10.3390/nu10030340 · Cited by 50
Pengnet, S., Sumarithum, P., Phongnu, N., Prommaouan, S., Kantip, N., Phoungpetchara, I., & Malakul, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1049818 · Cited by 45
“Consistent with other studies (Erion et al., 2013; Kim et al., 2019), we found increased ChREBP, SREBP-1c and nSREBP-1c expression as well as upregulated levels of their downstream targets, FAS and ACC, in the liver of fructose-fed rats.”
BackgroundKosuru, R., & Singh, S. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.015 · Cited by 47
Shi, J., Lu, J.-Y., Chen, H., Wei, C., Xu, X., Li, H., Bai, Q., Xia, F., Lam, S. M., Zhang, H., et al. (2020) · Diabetes · doi:10.2337/db19-0388 · Cited by 45
“Second, consistent with previous reports in global ChREBP knockouts (12,28), we provided direct biochemical evidence that liver contents of G6P, the allosteric activator of GS (31), were markedly elevated in the mutant mice, despite constant levels of expression and phosphorylation of GS.”
BackgroundInfluentialFlister, K. F. T., Pinto, B., França, L. M., Coêlho, C. F. F., dos Santos, P. C., Vale, C. C., Kajihara, D., Debbas, V., Laurindo, F. R. M., & Paes, A. M. D. A. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.09.007 · Cited by 47
Lei, Y., Hoogerland, J. A., Bloks, V. W., Bos, T., Bleeker, A., Wolters, H., Wolters, J. C., Hijmans, B. S., van Dijk, T. H., Thomas, R., et al. (2020) · Hepatology · doi:10.1002/hep.31198 · Cited by 41
McKeown, N. M., Dashti, H. S., Ma, J., Haslam, D. E., Jong, J. C. K., Smith, C. E., Tanaka, T., Graff, M., Lemaître, R. N., Rybin, D. V., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4475-0 · Cited by 42
“Recent data indicate that hepatic ChREBP is particularly responsive to fructose intake [15] and contributes to fructose-induced lipid and glycaemic abnormalities in animals and humans [16, 17].”
BackgroundSelf-citationMondoA drives muscle lipid accumulation and insulin resistance
Ahn, B. Y., Wan, S., Jaiswal, N., Vega, R. B., Ayer, D. E., Titchenell, P. M., Han, X., Won, K., & Kelly, D. P. (2019) · JCI Insight · doi:10.1172/jci.insight.129119 · Cited by 44
“fructose overload in liver, possibly playing a role in nonalcoholic fatty liver disease (31, 32).”
BackgroundRegulation of Glucose Production in the Pathogenesis of Type 2 Diabetes
Sargsyan, A., & Herman, M. A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1195-5 · Cited by 48
Self-citationGiussani, M., Lieti, G., Orlando, A., Parati, G., & Genovesi, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.792949 · Cited by 49
Glycerate from intestinal fructose metabolism induces islet cell damage and glucose intolerance
Wu, Y., Wong, C. W., Chiles, E. N., Mellinger, A. L., Bae, H., Jung, S., Peterson, T., Wang, J., Negrete, M., Huang, Q., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.007 · Cited by 45
Self-citationHieronimus, B., Medici, V., Bremer, A. A., Lee, V., Nuñez, M. V., Sigala, D. M., Keim, N. L., Havel, P. J., & Stanhope, K. L. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154356 · Cited by 47
Regulation of Liver Glucose and Lipid Metabolism by Transcriptional Factors and Coactivators
Ramatchandirin, B., Pearah, A., & He, L. (2023) · Life · doi:10.3390/life13020515 · Cited by 49
“Since ChREBP can activate G6pc expression, ingested fructose can be converted to glucose in the liver and be released into circulation to exacerbate hyperglycemia [45].”
BackgroundDietary Fructose Consumption and Triple-Negative Breast Cancer Incidence
Strober, J. W., & Brady, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00367 · Cited by 42
“Interestingly, carbohydrate-responsive element binding protein (ChREBP), a central metabolic regulator that couples carbohydrate catabolism and lipogenesis, is often upregulated as a result of high fructose feeding (52).”
BackgroundPark, G. S. H., Jung, S., Wellen, K. E., & Jang, C. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00614-x · Cited by 39
Heidari, A. (2020) · Advanced Science Engineering and Medicine · doi:10.1166/asem.2020.2635 · Cited by 38
The polyol pathway is an evolutionarily conserved system for sensing glucose uptake
Sano, H., Nakamura, A., Yamane, M., Niwa, H., Nishimura, T., Araki, K., Takemoto, K., Ishiguro, K., Aoki, H., Kato, Y., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001678 · Cited by 40
Liang, Y., Kaushal, D., & Wilson, R. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147943 · Cited by 45
Fructose and metabolic diseases: too much to be good
Shi, Y.-N., Liu, Y., Xie, Z., & Zhang, W. J. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001545 · Cited by 46
“Fructose can producemultiple intracellular carbohydrate metabolites that activate hepatic ChREBP independently of hepatic insulin signaling.([38,46,47]) In both rats and mice, high fructose feeding increases hepatic carbohydrate metabolites as well as the activity of ChREBP and its target genes.”
BackgroundInfluentialDietary fibre-adapted gut microbiome clears dietary fructose and reverses hepatic steatosis
Jung, S., Bae, H., Song, W., Chun, Y., Le, J., Alam, Y. H., Verlande, A., Chun, S. K., Kim, J., Kelly, M. E., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01356-0 · Cited by 43
“…CO 2 over time (left) and slope up to the maximum point (right) after 13 Cpalmitate administration ( n = 8, 7 mice). o , 13 CO 2 from 13 Cpalmitate after normalization to circulating 13 Excessive fructose catabolism in the liver has been shown to drive the gene expression of DNL enzymes 22,23 .”
Self-citationMoonira, T., Chachra, S. S., Ford, B. E., Marín, S., Alshawi, A., Adam-Primus, N. S., Arden, C., Al‐Oanzi, Z. H., Foretz, M., Viollet, B., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012533 · Cited by 35
“8G), which is a sensitive marker of ChREBP activation (49), was increased by 5- and 4-fold, respectively, by high G6P (25 mM glucose with S4048) and by high G3P (xylitol AOA) andwas also significantly induced bymoderate elevation in G6P and G3P with high glucose or xylitol without inhibitors but not with AOA alone.”
BackgroundHGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis
Sargsyan, A., Doridot, L., Hannou, S. A., Tong, W., Srinivasan, H., Ivison, R., Monn, R., Kou, H. H., Haldeman, J. M., Arlotto, M. E., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.153740 · Cited by 38
Self-citationAgius, L., Chachra, S. S., & Ford, B. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.594041 · Cited by 36
“The target genes of ChREBP include G6pc (23, 30) and the pentose phosphate pathway enzymes (8).”
BackgroundMethodInfluentialDietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII
Hieronimus, B., & Stanhope, K. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000653 · Cited by 34
ChREBP-β regulates thermogenesis in brown adipose tissue
Wei, C., Ma, X., Su, K., Qi, S., Zhu, Y., Lin, J., Wang, C., Yang, R., Chen, X., Wang, W., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0498 · Cited by 34
Fructose and fructose kinase in cancer and other pathologies
Jiang, H., Lin, Q., Ma, L., Luo, S., Jiang, X., Fang, J., & Lu, Z. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.06.006 · Cited by 33
Valenzuela, R., Farías, C., Muñoz, Y., Zúñiga‐Hernández, J., & Videla, L. A. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112676 · Cited by 40
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
“Finally, F1P also serves as an activator of PPAR-γ coactivator 1 beta (PGC-1β) protein, simultaneously increasing the expression of SREBP-1c and ChREBP via direct binding-mediated transactivation [49,63].”
BackgroundInfluentialThe hepatic compensatory response to elevated systemic sulfide promotes diabetes
Carter, R. N., Gibbins, M., Barrios-Llerena, M. E., Wilkie, S. E., Freddolino, L., Libiad, M., Vitvitsky, V., Emerson, B., Bihan, T. L., Brice, M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109958 · Cited by 33
“…are prece-dents for increased hepatic glucose production independent of insulin resistance, as found in the Nrf2 (cid:1) / (cid:1) mice (Meakin et al., 2014) and as driven by the transcription factor carbohydrate-response element-binding protein (ChREBP) (Uyeda and Repa, 2006; Kim et al., 2016).”
Zhang, X.-L., Wang, T.-Y., Targher, G., Byrne, C. D., & Zheng, M. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0048 · Cited by 33
“Activation of these two proteins upregulates the full complement of enzymes required for DNL, thereby contributing to the hepatic storage of free fatty acids [37-39].”
BackgroundZhang, G., Byun, H. R., Ying, Z., Blencowe, M., Zhao, Y., Hong, J. S., Shu, L., Krishnan, K. C., Gómez‐Pinilla, F., & Yang, X. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165569 · Cited by 33
Li, Y., Guo, W., Li, H., Wang, Y., Liu, X., & Kong, W. (2024) · Biomolecules · doi:10.3390/biom15010020 · Cited by 35
“Excessive fructose intake can up-regulate the carbohydrate response element-binding protein (ChREBP) in the liver, which activates glucose-6-phosphatase (G6Pase) and enhances gluconeogenesis to convert it into glucose [73].”
Ceciliano, T. C., Dutra, R. R., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105399 · Cited by 31
Daniel, P. V., Dogra, S., Rawat, P., Choubey, A., Khan, A. S., Rajak, S., Kamthan, M., & Mondal, P. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100714 · Cited by 34
ter Horst, K. W., Gilijamse, P. W., Demirkıran, A., van Wagensveld, B. A., Ackermans, M. T., Verheij, J., Romijn, J. A., Nieuwdorp, M., Maratos–Flier, E., Herman, M. A., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.08.014 · Cited by 33
“Thus, since fructose is preferentially metabolized by the liver, fructose more than glucose acutely raises intrahepatic carbohydrate intermediaries, activating ChREBP and promoting hepatic glycolysis and lipogenesis gene programs [20].”
BackgroundSelf-citationA Sweet Connection? Fructose’s Role in Hepatocellular Carcinoma
Dewdney, B., Roberts, A. A., Qiao, L., George, J., & Hebbard, L. (2020) · Biomolecules · doi:10.3390/biom10040496 · Cited by 31
“Additionally, fructose increases the expression of the gluconeogenic enzymes glucose-6-phosphatase (G6Pase) and fructose 1,6-biphosphatase 1 (FBP1), the glycolytic enzymes phosphofructokinase 1 (PFK1) and pyruvate kinase (PK), and increases glycogen and hepatic glucose production [32,33].”
BackgroundDrug development advances in human genetics‐based targets
Zhang, X., Yu, W., Li, Y., Wang, A., Cao, H., & Fu, Y. (2024) · MedComm · doi:10.1002/mco2.481 · Cited by 31
“…a series of metabolic transformations, it acts as a signaling molecule to promote adipose de novo synthesis and gluconeogenesis (Figure 3D), 245,249 leading to increased hepatic lipid synthesis and insulin resistance, and consequently, increasing the risk of developing obesity, NAFLD, and NASH.”
BackgroundHieronimus, B., Griffen, S. C., Keim, N. L., Bremer, A. A., Berglund, L., Nakajima, K., Havel, P. J., & Stanhope, K. L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070913 · Cited by 28
Payne, J. A., Proszkowiec‐Weglarz, M., & Ellestad, L. E. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00117.2019 · Cited by 31
“Under metabolic perturbation, CHREBP transactivation of glucose-6-phosphatase catalytic subunit activity expression is thought to increase gluconeogenesis and contribute to hyperglycemia (28).”
BackgroundFibroblast Growth Factor 21 Facilitates the Homeostatic Control of Feeding Behavior
Wu, C.-T., CHAFFIN, A. T. B., & Ryan, K. K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030580 · Cited by 24
Simons, P. I. H. G., Valkenburg, O., van de Waarenburg, M. P. H., van Greevenbroek, M. M. J., Kooi, M. E., Jansen, J. F. A., Schalkwijk, C. G., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2022) · Diabetologia · doi:10.1007/s00125-022-05790-7 · Cited by 28
“In addition, the carbohydrate regulatory element binding protein, which is one of the principal transcription factors that regulate de novo lipogenesis [40], activates glucose-6phosphatase and thereby contributes to increased hepatic glucose production [41].”
Background
Metadata
- Authors
- Kim, M.-S., Krawczyk, S. A., Doridot, L., Fowler, A. J., Wang, J. X., Trauger, S. A., Noh, H.-L., Kang, H. J., Meissen, J. K., Blatnik, M., Kim, J. K., Lai, M., & Herman, M. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of Massachusetts Chan Medical School (US)
- Pfizer (United States) (US)
- Broad Institute (US)
- Corresponding author
- Herman, Mark A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-09-26
- Volume
- 126
- Issue
- 11
- Pages
- 4372-4386
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5096918
- OpenAlex
- W2521958286
- Cited by
- 212
- References
- 69
- Citations by year
- 2026: 13 · 2025: 21 · 2024: 12 · 2023: 21 · 2022: 24 · 2021: 21 · 2020: 32 · 2019: 30 · 2018: 15 · 2017: 21 · 2016: 2
- FWCI
- 23.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Institutes of Health (5u2cdk093000-11)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK057521, U24DK093000, U2C-DK093000, R01DK100425, K23DK083439, T32DK007516)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- ChREBP, fructose, hepatic glucose production, hepatic insulin resistance, glucose-6-phosphatase, glucose-6-phosphate, FOXO1, hepatic steatosis, hypertriglyceridemia, hyperinsulinemia, impaired glucose tolerance, de novo lipogenesis, glycolytic genes, carbohydrate metabolism
- MeSH terms
- Forkhead Box Protein O1, Animals, Fatty Liver, Female, Fructose, Glucose, Glucose-6-Phosphatase, Glycolysis, Humans, Insulin, Insulin Resistance, Male, Nuclear Proteins, Transcription Factors, Signal Transduction, Glucose Intolerance, Mice, Knockout, Lipogenesis, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.